A detailed history of Price T Rowe Associates Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 139,400 shares of ACRS stock, worth $402,866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
139,400
Previous 139,400 -0.0%
Holding current value
$402,866
Previous $154,000 4.55%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.01 - $1.36 $29,929 - $40,300
29,633 Added 27.0%
139,400 $154,000
Q1 2024

May 15, 2024

BUY
$0.92 - $1.44 $1,151 - $1,802
1,252 Added 1.15%
109,767 $137,000
Q4 2023

Feb 14, 2024

SELL
$0.64 - $6.49 $13,678 - $138,704
-21,372 Reduced 16.45%
108,515 $114,000
Q3 2023

Nov 14, 2023

BUY
$6.56 - $10.95 $530,749 - $885,931
80,907 Added 165.18%
129,887 $890,000
Q2 2023

Aug 14, 2023

BUY
$7.89 - $10.64 $11,929 - $16,087
1,512 Added 3.19%
48,980 $508,000
Q1 2023

May 15, 2023

BUY
$7.07 - $17.95 $5,344 - $13,570
756 Added 1.62%
47,468 $385,000
Q4 2022

Feb 14, 2023

SELL
$14.33 - $18.37 $5,646 - $7,237
-394 Reduced 0.84%
46,712 $736,000
Q3 2022

Nov 14, 2022

BUY
$13.07 - $18.22 $118,636 - $165,382
9,077 Added 23.87%
47,106 $742,000
Q2 2022

Aug 15, 2022

BUY
$10.16 - $17.08 $65,633 - $110,336
6,460 Added 20.46%
38,029 $531,000
Q1 2022

May 16, 2022

SELL
$9.74 - $17.92 $7,538 - $13,870
-774 Reduced 2.39%
31,569 $544,000
Q4 2021

Feb 14, 2022

SELL
$12.27 - $18.49 $4,895 - $7,377
-399 Reduced 1.22%
32,343 $470,000
Q3 2021

Nov 15, 2021

SELL
$13.38 - $18.8 $123,564 - $173,618
-9,235 Reduced 22.0%
32,742 $589,000
Q2 2021

Aug 16, 2021

BUY
$17.08 - $29.6 $219,597 - $380,567
12,857 Added 44.15%
41,977 $737,000
Q1 2021

May 17, 2021

BUY
$5.86 - $27.73 $170,643 - $807,497
29,120 New
29,120 $734,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $193M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.